Archive:
Under the motto “Diabetes care by 2030 – how much progress do we dare?” Novo Nordisk Pharma presented its health policy event series “Diabetes 2030”, which has been taking place at the Royal Danish Embassy in Berlin for six years now. Pia Vornholt, Vice President Public Affairs of the Danish pharmaceutical company, welcomed the numerous participants – including doctors, representatives of health insurance companies and science, as well as patients – with the words: “We are facing major challenges that are innovative require solutions that can only be mastered together". This is exactly where “Diabetes 2030” comes into play as a platform for dialogue, with the stated aim of “discussing concrete recommendations for action” and, starting from diabetes, expanding the focus to other diseases associated with this disease.
30.11.2022
“How can it actually be that we have one of the most advanced and also one of the most expensive healthcare systems in the world, and that despite excellent universities and non-university institutions it is so difficult to bring innovation into care?” With this question, Prof. Dr. med. Peter Falkai, Clinic for Psychiatry and Psychotherapy at the Ludwig Maximilian University of Munich and Congress President of the 21st DKVF, at the press conference in advance of the 21st German Congress for Health Services Research.
30.11.2022
It is a purely diligent task to approach the question of how many of the health care research projects funded by the Innovation Fund and now terminated by a decision by the Innovation Committee were given “positive” or “negative” results, since the G-BA only offers PDF collections. The result speaks for itself, but depends on the interpretation. Some will say: At least 60% received a positive decision if you take into account the projects that received “no recommendation” but for which the results were at least forwarded. The others will notice the number of negative health care research projects: at least 38%.
30.11.2022
“The statutory health insurance system is fundamentally dependent on health services research,” explains Klaus Holetschek, State Minister in the Bavarian State Ministry of Health and Care, in an interview with “Monitor Health Services Research”. It is an important component for updating the GKV service catalog and - according to Holetschek - "of course it is important that the developed forms of care are also implemented in the near future". For this work to be done by health services research, data is essential and concrete requirements for a future health data use law must be specified. The Bavarian Minister of Health: “In my opinion, it is now important that the much-discussed Health Data Usage Act in Germany is introduced as quickly as possible.”
30.11.2022
In nur fünf Jahren will CompuGroup Medical (CGM) vom Software-Unternehmen zu einem bekannten Daten-Player, aber auch Enabler und Katalysator im Ökosystem Gesundheit werden, der für eine bessere Nutzung von Daten im Gesundheitssektor steht. Das erklärt Dr. Eckart Pech, Geschäftsführender Direktor Consumer and Health Management Information Systems von CGM, im Titelinterview mit „Monitor Versorgungsforschung“. Anlass des Gesprächs war die Übernahme des Datenanalysten INSIGHT Health, die dazu führen soll, zu „ganz neuen datengetriebenen Erkenntnissen“ zu kommen. Dies ist keine Zukunftsmusik, sondern mit dem ersten Produkt namens „Darwin Next Generation“ teilweise bereits Realität geworden, indem der INSIGHT Health-Datenpool historisierter Daten mit aktuellen Versorgungsdaten kombiniert wird.
30.11.2022
“How individual data donation can be conveyed as a contribution to medical progress” was the subtitle of the online talk format “Health Loft – Talk of Pioneers” organized by Pfizer. What can successful communication of data donation look like? What specific measures are needed to increase motivation to donate data? And what other hurdles need to be overcome to pave the way for the donation of health data? These and similar questions were examined and discussed in the online talk by experts from different perspectives.
29.11.2022
According to the National Care Guideline (NVL) for the treatment of T2DM, the use of various antidiabetic therapies should be gradual if patients are unable to achieve their individual therapy goals through lifestyle changes, e.g. B. by changing your eating habits and increasing physical activity.3 Known risk factors such as previous cardiovascular and renal diseases should also be taken into account when making individual treatment decisions. The combination of metformin with an SGLT-2 inhibitor (SGLT-2i) or a GLP-1 receptor agonist (GLP-1-RA) is recommended, for example, for patients who already have clinically relevant cardiovascular disease (CVD ).4 Furthermore, dipeptidyl peptidase-4 inhibitors (DPP-4i) in addition to metformin represent another treatment alternative for lowering blood sugar, but did not show significant benefits in reducing cardiovascular events. Cardiovascular diseases cause the highest expenditure in the German healthcare system and are responsible for up to 50% of the treatment costs of patients with T2DM due to the frequently required hospital stays.5 The present healthcare research study compares the direct healthcare costs of T2DM patients who receive treatment with the SGLT -2 inhibitor empagliflozin (EMPA) started with patients treated for the first time with DPP-4i or GLP-1-RA from the perspective of the statutory health insurance in Germany.
28.11.2022
The General Medicine Institute at the University Hospital Erlangen and the Chair of General Medicine at the FAU Erlangen-Nuremberg are probably one of the younger ones in the history of German health care research. The chair was only established in October 2013, but was the first regular general medical chair in Bavaria. Since then, the institute has been led by Professor Dr. med. Thomas Kühlein - who worked as a doctor in hospitals and general practitioners' practices for a long time - who, in addition to his role as chair, is also the medical director of the Eckental Medical Care Center (MVZ), part of the Erlangen University Hospital. Dr. phil. Susann Hueber has been research coordinator at the General Medicine Institute at Erlangen University Hospital since 2014.
28.11.2022
Breast cancer (BC) is the most common cancer among women in Germany, with around 69,000 new cases every year; 18,591 women died of BK in 2015 (Barnes et al., 2016). Approximately 70% of all newly diagnosed women with BK have a hormone receptor-positive tumor (HR+) who are eligible for primary adjuvant endocrine therapy (ET) with either tamoxifen (TAM) or an aromatase inhibitor (AI) (Franzoi et al., 2021) . Depending on the menopausal status, this standard therapy is taken daily for at least 5 years, significantly reduces the risk of BK recurrence and improves the overall survival of the patients (Waks & Winer, 2019, Font et al., 2022). Despite the proven effectiveness in preventing BK recurrence by 40%, approximately 50% of women take less than 80% of the prescribed dose. In addition, up to 50% of patients with BK discontinue their ET (Hadji et al., 2013; Moon et al., 2019; Peddie et al., 2021). It should be noted that both TAM and AI therapy can cause short- and long-term side effects in patients. These include hot flashes, myalgias and osteoporosis (Franzoi et al., 2021; Group et al., 2009). The occurrence of TAM- and AI-related side effects may therefore negatively impact a patient's persistence to ET. Persistence is defined as the continuation of drug use for the prescribed length of time (from initiation to discontinuation) while a patient adheres to the prescribed interval and dose of a dosing regimen (Cramer et al., 2008; Hadji et al., 2013). Recently, adherence to therapy and the persistence of ET in women with HR+ BK have been the subject of intense debate in the literature, since "non-adherence" to ET has been shown to be associated with an increased risk of disease recurrence (Font et al., 2019; Seneviratne et al ., 2015), for distant metastases (Blanchette et al., 2020; Lee et al., 2019) and for mortality (Inotai et al., 2021; Lao et al., 2019; Murphy et al., 2015). However, no study has yet investigated whether there is a connection between the health insurance company a woman has and her persistence in ET. The aim of this study was therefore to analyze persistence with TAM and AI and to show possible differences specific to health insurance companies.
28.11.2022
Diabetic polyneuropathy (DPN) is associated with significantly increased healthcare costs and thus an economic burden on society and the healthcare system (Happich et al. 2008; Khdour 2020; Shillo et al. 2019). A high number of hospital stays, need for care, incapacity to work as well as follow-up costs of DPN (e.g. amputations) and an overall greater use of healthcare resources are responsible for the higher medical costs (Sadosky et al. 2015; Schroeter/Hartung 2005; Ziegler 2020) and illustrate this Burden on patients suffering from DPN. The costs tend to increase as the burden of illness increases (Happich et al. 2008).